

Resource Summary Report

Generated by ASWG on Aug 9, 2026

EGFR antibody [EP38Y]

RRID:AB_869579

Type: Antibody

Proper Citation

Abcam Cat# ab52894, RRID:AB_869579

Antibody Information

URL: http://antibodyregistry.org/AB_869579

Proper Citation: Abcam Cat# ab52894, RRID:AB_869579

Target Antigen: EGFR antibody [EP38Y]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunoprecipitation; Western Blot; Immunohistochemistry - fixed; ICC/IF, IHC-P, IP, WB

Antibody Name: EGFR antibody [EP38Y]

Description: This monoclonal targets EGFR antibody [EP38Y]

Target Organism: Human, Rat, Mouse

Antibody ID: AB_869579

Vendor: Abcam

Catalog Number: ab52894

Record Creation Time: 20250820T033038+0000

Record Last Update: 20250820T162655+0000

Ratings and Alerts

No rating or validation information has been found for EGFR antibody [EP38Y].

No alerts have been found for EGFR antibody [EP38Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. *Cell stem cell*, 33(5), 800.

Ibrahim M, et al. (2026) NF1 Loss Remodels Tumor Niches for Immune Evasion. *bioRxiv* : the preprint server for biology.

Zhuang X, et al. (2026) Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery. *Cell chemical biology*, 33(4), 506.

Song H, et al. (2026) Hijacking ERAD for targeted degradation of transmembrane proteins. *Cell*, 189(6), 1768.

Pini A, et al. (2026) β 3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. *British journal of pharmacology*, 183(10), 2497.

Pang Z, et al. (2026) Mapping cellular targets of covalent cancer drugs in the entire mammalian body. *Cell*, 189(3), 725.

Wang Y, et al. (2025) Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. *Immunity*.

Tzouanas CN, et al. (2025) Hepatic adaptation to chronic metabolic stress primes tumorigenesis. *Cell*.

Sorensen JR, et al. (2025) Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury. *The Journal of physiology*, 603(23), 7531.

Bojang P, et al. (2025) LINE1 insertion into the NACC2 locus disrupts the HDM2 axis and activates lung oncogenic signaling. *NPJ precision oncology*, 9(1), 255.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. *Cancer cell*.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. *Scientific reports*, 15(1), 16964.

Ibrahim M, et al. (2025) NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma. *Cancer research*, 85(17), 3348.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Roy A, et al. (2024) Impact of Interleukin-6 Activation and Arthritis on Epidermal Growth Factor Receptor (EGFR) Activation in Sensory Neurons and the Spinal Cord. *International journal of molecular sciences*, 25(13).

Xia L, et al. (2024) Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. *Cancer research*, 84(3), 479.

Jin N, et al. (2024) Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study. *BMC medicine*, 22(1), 342.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Chen W, et al. (2024) GGT5 as a promising prognostic biomarker and its effects on tumor cell progression in gastric cancer. *Translational cancer research*, 13(8), 4459.

Dong Y, et al. (2024) TSPAN4 influences glioblastoma progression through regulating EGFR stability. *iScience*, 27(8), 110417.